Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Raised to $187 at RBC Capital

April 10, 2024 7:09 AM
RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $187.00 (from $182.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Analyst PT Change